Subsequent validation in the phase I/II ZENITH trial (NCT04199741) demonstrated [89Zr]Zr-DFO-SC16.56’s ability to discriminate DLL3 expression levels across metastatic sites, with tumor-to-background ratios >5.0 predicting Rova-T response (59). Here, DLL3 is linked to neoplasm.